Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149


Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.

Saraon P, Musrap N, Cretu D, Karagiannis GS, Batruch I, Smith C, Drabovich AP, Trudel D, van der Kwast T, Morrissey C, Jarvi KA, Diamandis EP.

J Biol Chem. 2012 Oct 5;287(41):34019-31. doi: 10.1074/jbc.M112.384438. Epub 2012 Aug 20.


Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey C, Jarvi K, Diamandis EP.

Mol Cell Proteomics. 2013 Jun;12(6):1589-601. doi: 10.1074/mcp.M112.023887. Epub 2013 Feb 26.


N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.

Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welén K.

Endocr Relat Cancer. 2010 May 18;17(2):469-79. doi: 10.1677/ERC-10-0015. Print 2010 Jun.


Expression of arginase II in prostate cancer.

Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW.

Int J Oncol. 2008 Feb;32(2):357-65.


Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.

Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC.

Cancer Res. 2004 Mar 15;64(6):2212-21.


Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy.

Johansson B, Pourian MR, Chuan YC, Byman I, Bergh A, Pang ST, Norstedt G, Bergman T, Pousette A.

Prostate. 2006 Sep 1;66(12):1235-44.


Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS.

Cancer Res. 2008 Jun 1;68(11):4447-54. doi: 10.1158/0008-5472.CAN-08-0249.


Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.

Malinowska K, Cavarretta IT, Susani M, Wrulich OA, Uberall F, Kenner L, Culig Z.

Prostate. 2009 Jul 1;69(10):1109-18. doi: 10.1002/pros.20956.


The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer.

Chang GT, Jhamai M, van Weerden WM, Jenster G, Brinkmann AO.

Endocr Relat Cancer. 2004 Dec;11(4):815-22.


Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance.

Srivastava SK, Bhardwaj A, Singh S, Arora S, McClellan S, Grizzle WE, Reed E, Singh AP.

Carcinogenesis. 2012 Jun;33(6):1149-57. doi: 10.1093/carcin/bgs134. Epub 2012 Mar 19.


Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.


Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.

Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1084-9. doi: 10.1073/pnas.1323102111. Epub 2014 Jan 6.


Proteomic signatures of angiogenesis in androgen-independent prostate cancer.

Karagiannis GS, Saraon P, Jarvi KA, Diamandis EP.

Prostate. 2014 Feb;74(3):260-72. doi: 10.1002/pros.22747. Epub 2013 Oct 26.


Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin.

Liu Z, Marquez M, Nilsson S, Holmberg AR.

Oncol Rep. 2009 Dec;22(6):1451-8.


Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.

Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.

Prostate. 2008 Mar 1;68(4):453-61. doi: 10.1002/pros.20723.


Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.

Yan L, Xing Z, Guo Z, Fang Z, Jiao W, Guo X, Xu Z, Fang Z, Holmberg A, Nilsson S, Liu Z.

PLoS One. 2013;8(2):e55790. doi: 10.1371/journal.pone.0055790. Epub 2013 Feb 7.


Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.

Fahrenholtz CD, Beltran PJ, Burnstein KL.

Mol Cancer Ther. 2013 Apr;12(4):394-404. doi: 10.1158/1535-7163.MCT-12-0648. Epub 2013 Jan 24.


Expression and role of Foxa proteins in prostate cancer.

Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ.

Prostate. 2006 Jul 1;66(10):1013-28.

Items per page

Supplemental Content

Write to the Help Desk